CTI BioPharma
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, CTI BioPharma sits in the top decile of US sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count).
CTI BioPharma: 28 sponsored US clinical trials, none currently recruiting.
CTI BioPharma sponsors 28 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 15 completed. 10 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Subjects, with 1 trials.
Top-decile sponsor footprint
CTI BioPharma ranks in the top decile of sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 28 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (53.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
28 total, page 1 of 1
Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects
NCT05657613
Study to Evaluate the Safety, Tolerability, and PK of Pacritinib
NCT05552183
PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
NCT04404361
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
NCT04884191
To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects
NCT02823171
Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects
NCT02807116
Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects
NCT02808455
To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects
NCT02807207
To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects
NCT02807051
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
NCT02055781
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
NCT01773187
Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects
NCT01638442
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
NCT01321541
Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00551733
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
NCT00269828
A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin
NCT00268853
Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)
NCT00106600
Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
NCT00060671
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
NCT00088530
Phase II CT-2103/Carboplatin in Ovarian Cancer
NCT00069901
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00054197
Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer
NCT00054184
Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00054210
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
NCT00060684
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
NCT00020969
Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
NCT00017069
Arsenic Trioxide in Treating Patients With Multiple Myeloma
NCT00017433
CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy
NCT00004026
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 8 |
| Phase 3 | 10 |
Therapeutic Areas
How the CTI BioPharma early-phase archive is shaped
28 indexed studies, none listed as recruiting (0% open); 15 completed (54%).
Phase mix: 10 late (III/IV) vs 18 early (I/II) (early-phase heavy).
Top condition: Healthy Subjects (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
CTI BioPharma: archived-pipeline peers nationwide
Peers matched on 28 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
CTI BioPharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 28 archived trials
- Axsome Therapeutics · 28 trials · 21% recruiting
- Benaroya Research Institute · 28 trials · 14% recruiting
- CAMC Health System · 28 trials · 11% recruiting
- Harvard Pilgrim Health Care · 28 trials · 4% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this CTI BioPharma page
28 registered trials is a research-attention snapshot, not an endorsement of CTI BioPharma or any single study.
- None of CTI BioPharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy Subjects is the condition CTI BioPharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Subjects trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. CTI BioPharma pipeline card: 28 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.